Boehringer Ingelheim reports Phase III survodutide results in obesity and type 2 diabetes
- In the 755-participant SYNCHRONIZE-2 trial, 76 weeks of survodutide produced up to 13.1% average weight loss versus 3.1% with placebo, using the efficacy estimand.
- Up to 79.3% of participants on survodutide lost at least 5% of body weight, compared with 32.7% on placebo.
- HbA1c fell by up to 1.21 percentage points from a baseline of 7.4%; waist circumference decreased by 11.1 cm.
- Gastrointestinal adverse events led to treatment discontinuation in 18% of survodutide recipients versus 1.2% on placebo.
Trial results
Boehringer Ingelheim reported that Phase III SYNCHRONIZE-2 met its co-primary endpoints in adults with overweight or obesity and type 2 diabetes. After 76 weeks, average weight loss reached 13.1% with survodutide versus 3.1% with placebo, using the efficacy estimand. At least 5% weight loss was achieved by up to 79.3% of participants on survodutide and 32.7% on placebo. Results were presented at the European Association for the Study of Diabetes meeting and published in The New England Journal of Medicine.
Metabolic measures and safety
HbA1c decreased by up to 1.21 percentage points from a baseline of 7.4%, compared with 0.03 points on placebo. Waist circumference fell by 11.1 cm versus 3.5 cm, and insulin sensitivity measures improved. Gastrointestinal events, mostly mild to moderate, were the most common adverse events; they led to treatment discontinuation in 18% of survodutide recipients and 1.2% of placebo recipients.
Further studies
A SYNCHRONIZE-1 substudy found preferential reductions in visceral and liver fat; muscle accounted for no more than 10% of total tissue lost. Survodutide is investigational, and its efficacy and safety have not been established. Boehringer plans to report SYNCHRONIZE-CVOT results later this year and has launched the Phase III SYNCHRONIZE-T2D trial.
Source: Boehringer Ingelheim